There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Novavax (NVAX) and MEI Pharma (MEIP) with bullish sentiments.
Novavax (NVAX)
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Novavax today and set a price target of $223.00. The company’s shares closed last Tuesday at $98.36.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 13.9% and a 45.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
Novavax has an analyst consensus of Moderate Buy, with a price target consensus of $220.80.
See today’s analyst top recommended stocks >>
MEI Pharma (MEIP)
LifeSci Capital analyst Adam Evertts PhD maintained a Buy rating on MEI Pharma today and set a price target of $9.00. The company’s shares closed last Tuesday at $2.83.
According to TipRanks.com, PhD is ranked #4705 out of 7011 analysts.
MEI Pharma has an analyst consensus of Strong Buy, with a price target consensus of $9.50, a 219.9% upside from current levels. In a report issued on October 12, Brookline Capital Markets also initiated coverage with a Buy rating on the stock with a $10.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
